Reduced ACTC1 Expression in CHD variances in organization, intracellular location, motor protein interactions and dynamics. 10 Six primary actin isoforms have been identified in higher vertebrates. As the main isoform in the adult heart, ACTC1 has shown to be the predominant form in early muscle development in most cultured cell lines as well as in the late stages of fetal development. 8, 11 Matsson et al reported that Morpholino knockdown of ACTC1 in chick embryos can result in delayed looping and reduced atrial septa, and concluded that reduced ACTC1 expression might lead to isolated ASD. 7 However, the level of ACTC1 expression in the sporadic-type of human CHD still remains unknown.
In this study, we have investigated the expression of ACTC1 in the heart tissues from patients with sporadic types of CHD, and correlated it with cardiomyocyte apoptosis, which might underlie the formation of CHD. 12 We also studied the expression of 2 essential genes, Caspase-3 and Bcl-2, in the cardiac tissues from such patients. To clarify whether reduced ACTC1 expression might induce apoptosis of cardiomyocytes, a small interfering RNA targeting, Actc1 (Actc1-siRNA), was also transfected into a rat embryonic cardiomyocytes cell line, H9C2. Thereafter, apoptotic cells were detected.
Methods

Surgical Pathology/Autopsied Specimens
Cardiac tissues were obtained as iced waste and paraffin-embedded surgical pathology/autopsy materials from 33 patients with CHD (Patient group, gestational age (GA) 18 weeks -49 months) and 12 age-matched autopsies where no structural or hemodynamic abnormalities of the heart were detected (Control group, GA 17 weeks -36 months) were obtained. Clinical data were retrieved from patient records. Tissue specimens were obtained from the free wall of the left ventricle or atrial appendage. Eleven samples were obtained 15-40 min after the patients' death, whilst the remaining samples were obtained during surgical operation or within 15 min after the patient's death (see Table 1 for details). Patients with syndromic CHD and other developmental anomalies were excluded. All samples were fixed with 10% buffered formalin (pH =7.4), and then embedded in paraffin for light microscopy. Four-μm-thick paraffin sections were stained with hematoxylin-eosin and Masson's trichrome for histopathological examination. Specimens with histopathological findings of autolysis were also excluded. The remaining tissue samples were stored at -80°C. Informed consent was obtained from the guardian of each patient, and the study protocol has conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the institution's human research committee.
RNA Isolation, Reverse Transcription and Real-Time PCR RNA was extracted from the heart tissues or H9C2 cells using the TRIzol Reagent (Invitrogen, Shanghai, China) according to the manufacturer's protocol. cDNA was synthesized from 3 μg of RNA using a RNA PCR kit (TaKaRa, Dalian, China). With 8 pairs of primers ( Table 2) , real-time RT-PCR was performed on an ABI 7500 system (Applied Biosystems, Foster City, CA, USA) in a 25 μl reaction mixture containing 12.5 μl of SYBR Green PCR Master mix (Applied Biosystems) and 1 μl cDNA. Relative cDNA concentrations were calculated from a standard curve using sequential dilutions of corresponding PCR fragments. The amplification program involved initial denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 10 s, and annealing and extension at 60°C Melting curve analyses were conducted after the completion of cycling with the aid of a temperature ramp (from 45°C to 95°C at 0.5°C/2 s) and continuous fluorescence monitoring to determine the specificity of PCR, which was confirmed with conventional gel electrophoresis. All reactions were repeated twice to ensure the reproducibility of the results.
Western Blotting
Frozen heart tissues from patients and controls and cultured H9C2 cells were lysed in buffer. The protein concentration of each lysate was determined with a bicinchoninic acid (BCA) kit (Keygen Biotech Co Ltd, Nanjing, China) according to the manufacturer's instruction. Total protein (30 μg) was applied to a 12% SDS-polyacrylamide gel. After electrophoresis, polyvinylidene fluoride (PVDF) membranes were washed in Tris-buffered saline containing 0.1% Tween-20, and then incubated with a primary antibody (monoclonal antibody to ACTC1; Santa Cruz, CA, USA, 1:200 diluted).
The membrane was incubated with a secondary antibody (1:4,000 diluted) and immuno-stained bands were detected with a ProtoBlot II AP System with a stabilized substrate (Promega, Madison, WI, USA). Beta-actin was used as the internal control.
Immunohistochemistry
Immunohistochemistry was performed in order to clarify the expression of ACTC1 protein in the disease tissue. For the start, heart tissues from patients were fixed with 10% buffered formalin (pH =7.4) and embedded in paraffin. Subsequently, 4-μm sections were prepared by sequential incubation with an anti-ACTC1 monoclonal antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) at a 1:100 dilution. Normal mouse serum (Santa Cruz, CA, USA) at the same dilution was used as the negative control. After the staining, images were acquired with an Axiophot microscope equipped with a high sensibility color camera (Axiocam, Carl Zeiss). A set of images was analyzed to assess the percentage of isoactinpositive cardiomyocytes using KS400 software (Kontron System; Zeiss Vision, Oberkochen, Germany).
Detection of Apoptotic Cardiomyocytes in Tissue Sections
A terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay was used to identify doublestranded DNA fragmentation; characteristics of DNA degradation due to apoptosis. Briefly, tissue slides were deparaffinized and treated with proteinase K (20 μg/ml) for 20 min at room temperature. The slides were then quenched in 2.0% hydrogen peroxide. After rinsing in phosphate-buffered saline (PBS, pH 7.4), specimens were incubated in 1× equilibration buffer for approximately 10-15 s. The slides were then incubated with terminal deoxynucleotidyl transferase (rTdT) for 1 h at 37°C, blocked with a stop/washing buffer, and incubated with peroxidase-conjugated anti-digoxigenin antibody for 30 min at room temperature. Finally, the slides were stained with diaminobenzidine (DAB; Promega). Nuclear staining by hematoxylin was performed as the counter-stain. A commercially available human lymph node section was used as the positive control. A negative control of the TUNEL assay was set by staining human heart tissue in the same manner but without rTdT enzyme incubation. Subsequently, cardiac-specific immunostaining was performed using a primary anti-ACTC1 antibody (Santa Cruz Biotechnology Inc) and a secondary reaction using the streptavidin-alkaline phosphatase system to clarify the type of positive cells. For each specimen, the proportion of TUNEL-positive cardiomyocytes was expressed as the ratio of cardiomyocytes expressing TUNEL over the total number of cardiomyocytes per field. For each case, 100 random fields were counted. Approximately 3-5 sections obtained at a distance of 100 μm for each tissue block were used. To avoid potential bias due to selection of fields with different cardiomyocytes density, approximately 1,500 cardiomyocyte nuclei were investigated for each optical field (objective lens, ×20). The total numbers of cardiomyocytes counted ranged from 450×10 3 to 750×10 3 . Only actin-positive cells with well-organized sarcomeric striation were identified as cardiomyocytes, whereas actin-negative cells without striation (such as vascular smooth-muscle cells of an intramyocardial arteriole and rare interstitial cells) Figure 1 . Expression of the Cardiac α actin 1 gene (ACTC1) as determined by the abundance of mRNA and protein in the cardiac tissues from patients with congenital heart disease (CHD). (A) As shown, the mRNA of ACTC1 was significantly reduced in the disease tissues (lanes 2, 4, 6) compared with the controls (lanes 1, 3, 5) . The specificity of real-time RT-PCR was confirmed with conventional gel electrophoresis. (B) ACTC1 proteins, as detected by Western blotting, was reduced accordingly (lanes 4-6) compared with the controls (lanes 1-3) . **P<0.01 vs control. (C) The patient group was divided into 2 sub-groups based on the expression of ACTC1. Samples with reduced ACTC1 expression were designated as Group 1, and the remainder were designated as Group 2. (D) As confirmed by Western blotting, the abundance of ACTC1 protein was consistent with that of ACTC1 mRNA from the same patients. **P<0.01 vs control and Group 2. No significant change was detected between Group 2 and the control. (E) Expression of the ACTC1 gene in the cardiac tissues determined by immunohistochemistry. Staining was mainly restricted in the cytoplasm, which was intense in cardiac tissues of controls and Group 2 patients (b and d) but decreased in Group 1 (c) patients. Pictures were amplified to ×400. Scale=30 μm. Negative control was also shown (a). ○, control; ▲, CHD group; ▲, Group 1; △, Group 2. JIANG HK et al. . ACTC1 proteins co-localized with markers of apoptosis. Double positive staining (nuclear staining for DNA fragmentation at TUNEL, and cytoplasmic staining for ACTC1) within the same cardiomyocytes is shown. The correlation between TUNEL-positive cardiomyocytes and ACTC1 expression in patients with CHD is shown in (E) (▲, Group 1; ▲, Group 2; r=-0.918, P<0.01). Expression of Caspase-3 and Bcl-2 genes, as determined by real-time RT-PCR, in the diseased tissues with down-regulated ACTC1 (Group 1) or normal expression (Group 2) and controls is shown in (F) and (G). **P<0.01 vs control and Group 2. ACTC1, Cardiac α actin 1 gene; ns, not significant; TUNEL, transferase-mediated dUTP nick end-labeling. Reduced ACTC1 Expression in CHD were excluded. The nuclei were counted by 2 observers who were blinded to the experimental conditions. Cell Culture and Actc1-siRNA Transfection H9C2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. After the cells had grown to confluence, they were placed in a quiescent medium (0.5% fetal bovine serum) for 16 h. To silence Actc1 gene expression, we performed siRNA transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). A short interfering RNA targeting rat Actc1 (Actc1-siRNA) was designed and synthesized by GenePharma, Shanghai, China. The sequences of Actc1-siRNA were as follows: 5'-GAAACUACUUAUAACAGCATT-3' and 5'-UGCUG-UUAUAAGUAGUUUCGT-3'. siRNA transfection was performed according to the manufacturer's instruction (Targeting Systems, San Diego, CA, USA). Actc1-siRNA or scramble siRNA (negative control) was transfected into H9C2 cells at the final concentration of 100 nmol/L. The efficacy of Actc1 knockdown was assessed by real-time RT-PCR (48 h after transfection) and Western blotting (72 h after transfection).
Detection of Apoptotic H9C2 Cells
Apoptosis in H9C2 cells 72 h after transfection with Actc1-siRNA was assayed with an Annexin V-FITC Apoptosis Detection Kit (Miltenyi, Germany). At the end of incubation, the cells were gently washed once with PBS and incubated for 15 min at room temperature with 120 μl of annexinbinding buffer containing 10 μl of fluorescein isothiocyanate (FITC)-conjugated annexin V and 1 μl of 100 μg/ml PI. The staining mixture was then removed and replaced with 120 μl of annexin-binding buffer. The cells were viewed immediately using an Olympus IX-70 inverted fluorescent microscope equipped with filters appropriate for fluorescein and rhodamine. Thereafter, samples were analyzed by flow cytometry (FACScaliber, Becton Dickinson, Franklin Lakes, NJ, USA) for viable (annexin V-negative and PI-negative), early apoptotic (annexin V-positive, PI-negative), and late apoptotic/ secondary necrotic cells (annexin V-positive and PI-positive). The extent of apoptosis was quantified as the percentage of annexin V-positive cells. The findings in Actc1-silenced H9C2 cells were confirmed by TUNEL assay using a commercial kit (Promega). Briefly, after removal of the floating cells, adherent cells in 2-well chamber slides were fixed and stained according to the manufacturer's instructions. Apoptosis was defined as TUNEL-positive nuclei in cells with morphological features of cell death (cell shrinkage, aggregation of chromatin into dense masses, and cell fragmentation). The mean number of apoptotic cells (TUNEL positive) from 3 random fields (×40) in each well was counted.
Statistical Analysis
All values were recorded as mean ± SD. Statistical significance between the groups was determined by a 1-way ANOVA. A P<0.05 was considered to be statistically significant. All statistical analyses were performed with by using SPSS software (version 13.0; SPSS Inc, USA).
Results
Reduced ACTC1 in the Heart Tissues From CHD Patients
As shown in Figure 1 , 26 out of the 33 samples (78.8%) from patients with CHD showed reduced ACTC1 mRNA compared with controls. Western blotting and an immunohistochemistry assay also confirmed that the ACTC1 protein was significantly down-regulated accordingly. We have further divided our patients into 2 sub-groups based on the mRNA levels of ACTC1 normalized to the mean value of the control group. Those with reduced ACTC1 expression were designated as Group 1 (n=26, tetralogy of Fallot (TOF) 4, ASD 11, ventricular septal defect (VSD) 7, atrioventricular septal defect (AVSD) 4), and the remainder were designated as Group 2 (n=7, ASD 4, VSD 3). As confirmed by Western blotting, the level of ACTC1 protein was consistent with that of ACTC1 mRNA in samples from the same patients. However, no significant changes were found between Group 2 and the controls (Figures 1C,D) .
Elevated TUNEL-Positive Cardiomyocytes in CHD Patients
TUNEL-positive cardiomyocytes were clearly detected in both controls (Figure 2A) and patients featured down-regulated ACTC1 expression (Group 1, n=26, Figure 2B) or Figure 3 . H9C2 cells transiently transfected with Actc1-specific small interfering RNA (Actc1-siRNA) or a scramble siRNA (negative control). Actc1 mRNA (A) was determined by realtime PCR, and Actc1 protein was detected by Western blotting (B). Beta-actin was used as controls. **P<0.01 vs negative control. ACTC1, Cardiac α actin 1 gene. JIANG HK et al.
normal expression (Group 2, n=7, Figure 2C ). To clarify whether apoptotic death of cardiomyocytes has increased in CHD patients, we also determined the proportion of TUNELpositive cardiomyocytes in each group. As found, the ratio of the latter to the total of cardiomyocytes was significantly higher in patients with down-regulated ACTC1 compared with Group 2 and the controls (5.77±2.23% vs 1.45±0.44%, 1.25±0.81%, P<0.01, respectively; Figure 2D) . Again, no difference was found between Group 2 and the control group in regard to the proportion of TUNEL-positive cardiomyocytes (1.45±0.04% vs 1.25±0.08%, P>0.05; Figure 2D) .
Next, we attempted to correlate the proportion of TUNELpositive apoptotic cardiomyocytes with the expression of ACTC1 in diseased samples. As shown in Figure 2E , a high 
Expression of Caspase-3 and Bcl-2 Genes in Cardiac Tissues
As shown in Figures 2F,G , the expression of Caspase-3 was higher in diseased tissues featuring decreased ACTC1 expression than in controls and in Group 2 (P<0.01). Meanwhile, the expression of Bcl-2 in patients with down-regulated ACTC1 was lower than that in Group 2 and in the controls (P<0.01).
Reduced Actc1 Expression Might Induce H9C2 Apoptosis
Reduced Actc1 mRNA was detected at 48 h by RT-PCR and at 72 h by Western blotting after the transfection (Figures 3A,  B) . As shown in Figure 4A , more TUNEL-positive cardiomyocytes were detected in Actc1-silenced H9C2 cells than in control cells (58.79±0.32 vs 1.89±0.13, P<0.01). Apoptotic cells were also evaluated by flow cytometry. Annexin V-positive cells had increased remarkably in cells transfected with Actc1-siRNA compared with the negative control (52.92± 0.29 vs 2.16±0.09, P<0.01; Figure 4B ). Furthermore, as determined by real-time RT-PCR, the expression of the Caspase-3 gene had increased after the transfection, whilst that of the Bcl-2 gene had decreased compared with the controls (P< 0.01; Figures 4C,D) .
Discussion
As essentially the only actin expressed in embryonic heart muscle, 8,13 ACTC1 has a remarkably conserved amino acid sequence, probably more so than any other proteins. This alone seems to suggest that genetic lesions in ACTC1, though only transiently expressed in cardiomyocytes, might cause cardiovascular phenotypes. A rich variety of ACTC1 mutations has been identified in dilated cardiomyopathy and hypertrophic cardiomyopathy. 14 Among such patients, septal defects have been identified as additional features. 15-17 Patients with contiguous gene syndromes and 15q deletions spanning the ACTC1 gene have also been described. 18 The presented phenotypes, including ASD, VSD and TOF, have suggested the importance of ACTC1 for the formation of cardiac structure. In 2 families featuring isolated ASD, Matsson et al have identified dominant-type ACTC1 mutations. The screening of 408 sporadic CHD cases had identified 1 case with ASD and a 17-bp deletion in the ACTC1 gene, predicting a nonfunctional protein. Therefore, mutations or deletions of the ACTC1 gene might affect its interactions with actomyosin and binding with regulatory proteins. 7 In this study, the majority of patients with sporadic CHD (78.8%) showed a reduced ACTC1 expression, suggesting the latter might contribute to the onset of CHD.
As shown by others, Morpholino knockdown of ACTC1 in chick embryos can lead to delayed bulboventricular looping and reduced atrial septum due to the affected actin polymerization. 7 Down-regulation of ACTC1, due to Smad4 deletion, can lead to a dramatic decrease in cardiomyocyte proliferation and severe morphological defects including thin compact layer, disorganized trabeculae and VSD. 19 During the gestation, proliferation of cardiomyocytes is necessary for coping with the increasing hemodynamic load. 5 As the heart has to function through its own development, hemodynamic forces might also participate in its morphogenesis. In zebrafish, altering hemodynamics mechanically or genetically can both have a profound impact on heart morphogenesis. 20, 21 In mice, 1 study had pinpointed altered hemodynamics as a key intermediate between altered outflow tract morphogenesis and signaling events during remodeling of branchial arch arteries. 22 Based on our findings, we propose that the reduced expression of ACTC1 might result in decreased cardiomyocyte proliferation, which might lead to the disturbance of hemodynamics during embryonic development, resulting in abnormal morphogenesis of the heart.
Besides cell proliferation, apoptosis has also been proposed as a key process during organogenesis. 23-25 Transgenic and knockout studies both provided strong evidence for aberrant patterns of apoptosis resulting in CHD, including septation anomalies. 25 Studies have revealed that actin plays a key role in apoptosis regulation. 26 As discovered recently, the death of adult myocytes as terminal cells is not genetically programmed as with apoptosis. 27-29 In this study, cardiomyocyte apoptosis was detected in embryonic or infantile tissues. The proportion of apoptotic cardiomyocytes appeared to be higher in patients with decreased ACTC1, and is strongly correlated with the latter. Furthermore, more TUNEL-positive/Annexin V-positive cardiomyocytes were detected in Actc1-silenced H9C2 cells. Together with an altered expression of Caspase-3 and Bcl-2, these have clearly indicated that reduced Actc1 expression might induce H9C2 apoptosis in vitro.
As reported, homozygous deletion of Actc1 in mice can lead to functional and structural disturbances of the heart, which might be due to disorganized development of actomyosin filaments in the affected cardiomyocytes because of the induced apoptosis in the defective cardiomyocytes and disrupted differentiation. 12 Disruption of the actin-filament network in the hypodynamic heart has been associated with apoptosis. 12, 30 Notably, reduced expression of the ACTC1 gene might also evoke a signal for apoptosis and result in the observed defects. 12,30, 31 The addition of a F-actin-stabilizing drug, JASP (Jasplakinolide), to Jurkat T-cells can rapidly induce apoptosis, which is accompanied by an increase in caspase-3 activation. 32 This seems in keeping with our findings of the over-expression of Caspase-3 in CHD patients with decreased ACTC1 expression (in vivo) and in Actc1-silenced H9C2 cells (in vitro). Notably, down-regulated Bcl-2 expression was also detected in cardiac tissues from such patients or Actc1-silenced H9C2 cells. Inhibition of actin depolymerization-stimulated apoptosis and Bcl-2 might rescue the cell death induced by direct disruption of the actin cytoskeleton. 33, 34 A plausible explanation to this might be that the reduced ACTC1 expression might promote apoptosis by stimulating expression of Caspase-3, the essential executor for apoptosis, whilst inhibiting the expression of Bcl-2, an anti-apoptotic protein. 35 The increased apoptosis of cardiomyocytes and impaired contractility caused by actin loss during cardiogenesis might lead to hemodynamic disturbance, which is responsible for abnormal morphogenesis of the heart. In return, exposure to the pressure overload caused by mechanical stress from blood accumulation owing to the cardiac deformities might increase apoptosis. This might help to explain the universally observed increased cardiomyocyte apoptosis in our patients.
Conclusion
Based on the above results, we propose that reduced ACTC1 expression at a crucial stage during heart development might contribute to the onset of CHD owing to increased apoptosis of cardiomyocytes.
